This document is a draft for comments from July 2019, published in the WHO Drug Information, Vol 33, No. 3, 2019. It is a consultation document from the Medicines Quality Assurance working group of the World Health Organization (WHO). The policy was initiated following discussions about establishing guidelines for the remaining shelf-life (RSL) of medical products upon delivery. The document emphasizes the importance of a harmonized approach to ensure the availability of quality medical products within their shelf-life. The policy aims to balance the enforcement of the remaining shelf-life policy with the availability of medical products, promote efficient processing in the supply chain, prevent wastage, stock-outs, and the dumping of medical products, among other objectives. The document provides detailed guidelines on the remaining shelf-life of medical products upon delivery, including principles, considerations, and examples. It also includes a glossary of terms and references to further reading and related WHO guidelines. The policy is intended to be implemented by all stakeholders in the supply chain of medical products and is recommended for consideration in national policies.
You can submit a specific query to QUAMED experts by clicking on the button below. We will send relevant answers directly to your mailbox.
Submit Query
The information provided on this Web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government.
ISO 9001:2015 - FS766975
© 2024 - QUAMED
Content of this site is licensed under a Creative Commons License- BY Attribution